A brain-vectored angiopep-2 based polymeric micelles for the treatment of intracranial fungal infection

Biomaterials

Volumn 33, Issue 28, 2012, Pages 6898-6907

  Shao, Kun ^a   Wu, Jiqin ^b   Chen, Zhongqing ^b   Huang, Shixian ^a   Li, Jianfeng ^a   Ye, Liya ^c   Lou, Jinning ^c   Zhu, Liping ^b   Jiang, Chen ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

Amphotericin B; Angiopep 2; Blood brain barrier; Intracranial infection; P gp; Polymeric micelles

Indexed keywords

AMPHOTERICIN B; ANGIOPEP-2; BLOOD-BRAIN BARRIER; INTRACRANIAL INFECTION; P-GP; POLYMERIC MICELLE;

DRUG THERAPY; FUNGI; MICELLES;

POLYMERS;

AMPHOTERICIN B CHOLESTEROL SULFATE; ANGIOPEPTIN; ANGIOPEPTIN 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFECTION; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; HISTOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MALE; MICELLE; MOUSE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; BLOOD-BRAIN BARRIER; CRYPTOCOCCUS NEOFORMANS; DRUG CARRIERS; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; MENINGOENCEPHALITIS; MICE; MICELLES; MICROSCOPY, CONFOCAL; P-GLYCOPROTEIN; PEPTIDES; POLYETHYLENE GLYCOLS; SPECTROMETRY, FLUORESCENCE; VERAPAMIL;

FILOBASIDIELLA NEOFORMANS; MURINAE;

EID: 84864003094     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.06.050     Document Type: Article

References (40)

1. Mitchell T.G., Perfect J.R. Cryptococcosis in the era of AIDs-100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995, 8(4):515-548.
2. Stevens D.A., Denning D.W., Shatsky S., Armstrong R.W., Adler J.D., Lewis B.H. Cryptococcal meningitis in the immunocompromised host: intracranial hypertension and other complications. Mycopathologia 1999, 146(1):1-8.
3. Pyrgos V., Mickiene D., Sein T., Cotton M., Fransesconi A., Mizrahi I., et al. Effects of immunomodulatory and organism-associated molecules on the permeability of an in vitro blood-brain barrier model to amphotericin B and fluconazole. Antimicrob Agents Chemother 2010, 54(3):1305-1310.
4. Dotis J., Iosifidis E., Roilides E. Central nervous system aspergillosis in children: a systematic review of reported cases. Int J Infect Dis 2007, 11(5):381-393.
5. Roden M.M., Zaoutis T.E., Buchanan W.L., Knudsen T.A., Sarkisova T.A., Schaufele R.L., et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005, 41(5):634-653.
6. Saag M.S., Graybill R.J., Larsen R.A., Pappas P.G., Perfect J.R., Powderly W.G., et al. Practice guidelines for the management of cryptococcal disease. Infect Dis Soc of America Clin Infect Dis 2000, 30(4):710-718.
7. Groll A.H., Giri N., Petraitis V., Petraitiene R., Candelario M., Bacher J.S., et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000, 182(1):274-282.
8. Clemons K.V., Sobel R.A., Williams P.L., Pappagianis D., Stevens D.A. Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. Antimicrob Agents Chemother 2002, 46(8):2420-2426.
9. Gallis H.A., Drew R.H., Pickard W.W. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990, 12(2):308-329.
10. Hiemenz J.W., Walsh T.J. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis Suppl 1996, 2:S133-S144.
11. Capilla J., Clemons K.V., Sobel R.A., Stevens D.A. Efficacy of amphotericin B lipid complex in a rabbit model of coccidioidal meningitis. J Antimicrob Chemother 2007, 60(3):673-676.
12. Hamill R.J., Sobel J.D., El-Sadr W., Johnson P.C., Graybill J.R., Javaly K., et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis 2010, 51(2):225-232.
13. Bicanic T., Wood R., Meintjes G., Rebe K., Brouwer A., Loyse A., et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 2008, 47(1):123-130.
14. Shao K., Huang R.Q., Li J.F., Han L., Ye L.Y., Lou J.N., et al. Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. J Control Release 2010, 147(1):118-126.
15. Demeule M., Currie J.C., Bertrand Y., Ché C., Nguyen T., Régina A., et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem 2008, 106(4):1534-1544.
16. Régina A., Demeule M., Ché C., Lavallée I., Poirier J., Gabathuler R., et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol 2008, 155(2):185-197.
17. Ke W., Shao K., Huang R., Han L., Liu Y., Li J.F., et al. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimers. Biomaterials 2009, 30(36):6976-6985.
18. Bendayan R., Lee G., Bendayan M. Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc Res Tech 2002, 57(5):365-380.
19. Golden P.L., Pardridge W.M. Brain microvascular P-glycoprotein and a revised model of multidrug resistance in brain. Cell Mol Neurobiol 2000, 20(2):165-181.
20. Breedveld P., Beijnen J.H., Schellens J.H. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 2006, 27(1):17-24.
21. Risovic V., Sachs-Barrable K., Boyd M., Wasan K.M. Potential mechanisms by which Peceol increases the gastrointestinal absorption of amphotericin B. Drug Dev Ind Pharm 2004, 30(7):767-774.
22. Sachs-Barrable K., Lee S.D., Wasan E.K., Thornton S.J., Wasan K.M. Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections. Adv Drug Deliv Rev 2008, 60(6):692-701.
23. Ishizaki J., Ito S., Jin M., Shimada T., Ishigaki T., Harasawa Y., et al. Mechanism of decrease of oral bioavailability of cyclosporin A during immunotherapy upon coadministration of amphotericin B. Biopharm Drug Dispos 2008, 29(4):195-203.
24. Lou J.N., Gasche Y., Zhang L., Critico B., Monso-Hinard C., Juillard P., et al. Differential reactivity of brain microvascular endothelial cells to TNF reflects the genetic susceptibility to cerebral malaria. Eur J Immunol 1998, 28:3989-4000.
25. Xie Y., Ye L.Y., Zhang X.B., Hou X.P., Lou J.N. Establishment of an in vitro model of brain-blood barrier. Beijing Da Xue Xue Bao 2004, 36(4):435-438.
26. Mei Z., Yan P., Situ B., Mou Y., Liu P. Cryptotanshinione inhibits β-amyloid aggregation and protects damage from β-amyloid in SH-SY5Y Cells. Neurochem Res 2012, 37(3):622-628.
27. Ke J.H., Lin J.J., Carey J.R., Chen J.S., Chen C.Y., Wang L.F. A specific tumor-targeting magnetofluorescent nanoprobe for dual-modality molecular imaging. Biomaterials 2010, 31(7):1707-1715.
28. Yang T.F., Chen C.N., Chen M.C., Lai C.H., Liang H.F., Sung H.W. Shell-crosslinked Pluronic L121 micelles as a drug delivery vehicle. Biomaterials 2007, 28(4):725-734.
29. Chiller T.M., Luque J.C., Sobel R.A., Farrokhshad K., Clemons K.V., Stevens D.A. Development of a murine model of cerebral aspergillosis. J Infect Dis 2002, 186(4):574-577.
30. Chiller T.M., Sobel R.A., Luque J.C., Clemons K.V., Stevens D.A. Efficacy of amphotericin B or itraconazole in a murine model of central nervous system Aspergillus infection. Antimicrob Agents Chemother 2003, 47(2):813-815.
31. Kamberi P., Sobel R.A., Clemons K.V., Stevens D.A., Pappagianis D., Williams P.L. A murine model of coccidioidal meningitis. J Infect Dis 2003, 187(3):453-460.
32. Wang X., Li J., Wang Y., Koenig L., Gjyrezi A., Giannakakou P., et al. A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. ACS Nano 2011, 5(8):6184-6194.
33. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
34. Bang J.Y., Song C.E., Kim C., Park W.D., Cho K.R., Kim P.I., et al. Cytotoxicity of amphotericin B-incorporated polymeric micelles composed of poly(DL-lactide-co-glycolide)/dextran graft copolymer. Arch Pharm Res 2008, 31(11):1463-1469.
35. Larsen R.A., Bauer M., Thomas A.M., Graybill J.R. Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis. Antimicrob Agents Chemother 2004, 48(3):985-991.
36. Clemons K.V., Espiritu M., Parmar R., Stevens D.A. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 2005, 49(12):4867-4875.
37. Wang L.H., Fielding R.M., Smith P.C., Guo L.S. Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil) and Fungizone after repeated dosing in rats. Pharm Res 1995, 12(2):275-283.
38. Clemons K.V., Stevens D.A. Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob Agents Chemother 1998, 42(4):899-902.
39. Chow E.K., Zhang X.Q., Chen M., Lam R., Robinson E., Huang H., et al. Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment. Sci Transi Med 2011, 3(73). 73ra21.
40. Wong H.L., Rauth A.M., Bendayan R., Manias J.L., Ramaswamy M., Liu Z., et al. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res 2006, 23(7):1574-1584.